Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study terminated prematurely.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of the ATS 3f® Aortic Bioprosthesis, Model 1000 (Equine Pericardial Bioprothesis) size 19mm in a patient population undergoing isolated aortic valve replacement of his/her native aortic valve, or replacement of a failed prosthesis.
A multi-center, post market, non-randomized trial, designed to obtain safety and efficacy data from patients implanted with the size 19mm Model 1000 heart valve. Each enrolled patient will be followed until one year post-implantation. Data will be collected both retrospectively and prospectively, on patients who were implanted from 1-Jan-2009 to 31-Dec-2009 with the 19mm Model 1000. The data collected will be pooled with the data currently collected, under the U.S. Food and Drug Administration (FDA) IDE Number G01284 for submission to the U.S. FDA.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Replacement aortic heart valve | ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm | Device | Replacement aortic heart valve |
|
| Measure | Description | Time Frame |
|---|---|---|
| New York Heart Association (NYHA) Functional Classification | The NYHA classifications will be analyzed to demonstrate if implanting the of the study valve leads to an improvement in this clinical parameter for the patient. | <30 days / discharge, whichever comes last, 3-6 months, 11-14 months |
| Blood Data | Blood data will be analyzed preoperative and postopertive to demonstrate if implanting of the study valve results in acceptable parameters for Serum Lactate Dehydrogenase (SLDH), Haptoglobin, Hematocrit and Reticulocyte parameters. Platelet and white blood cell count will also be analyzed. | <30 days / discharge, whichever comes last, 3-6 months, 11-14 months |
| Adverse/complication rates | To demonstrate that the adverse/complication rates for the Model 1000 Bioprosthesis are less than two times the Objective Performance Criteria (OPCs) established by the FDA for severe complications. | <30 days / discharge, whichever comes last, 3-6 months, 11-14 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who were previously implanted with the ATS 3f Aortic Bioprosthesis Model 1000 (size 19mm) between the dates 1-Jan-2009 and 31-Dec-2009 and who meet the eligibility criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mike Boulware, PhD | Medtronic | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| McGill University Health Centre, Royal Victoria Hospital | Montreal | Quebec | H3A 1A1 | Canada |
Not provided
| Label | URL |
|---|---|
| Corporate Website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D006349 | Heart Valve Diseases |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided